Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

IL33 in pancreatic cancer-pro- or antitumor?

Trends in cancer - 1 May 2026

Sharma Supriya, Dixit Ajay

Abstract excerpt

Interleukin 33 (IL33) in the tumor microenvironment of pancreatic cancer has been linked to both pro- and antitumor immune responses, suggesting a context-dependent role. Herein, we discuss the current understanding and challenges of therapeutically targeting IL33 signaling in pancreatic cancer.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents, Immunological
Share to Carcinoma, Pancreatic Ductal
Share to Gene Expression Regulation, Neoplastic

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Interleukin-1 Receptor-Like 1 Protein

Share to Interleukin-33

Share to Molecular Targeted Therapy

Share to Pancreatic Neoplasms

Share to Tumor Microenvironment

Source

Identifiers

PMID: 41813474
DOI: 10.1016/j.trecan.2026.01.009

Genes

IL33

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 24 Oct 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

IL33 in pancreatic cancer-pro- or antitumor?PMID 41813474Read ↗

Pancreatic tumor initiation: the potential role of IL-33.Semantic proximity Read ↗

IL-33 biology in cancer: An update and future perspectivesSemantic proximity Read ↗

Interleukin-33: Friend or Foe in Gastrointestinal Tract Cancers?Semantic proximity Read ↗

Mechanistic Insights into the Roles of the IL-17/IL-17R Families in Pancreatic CancerSemantic proximity Read ↗

Tumor suppressor p53 deficiency increases tumor immunogenicity through promoting IL33-mediated anti-tumor immune responsesSemantic proximity Read ↗

Exploiting inflammation for therapeutic gain in pancreatic cancer.Semantic proximity Read ↗

Inflammation and pancreatic cancer: disease promoter and new therapeutic target.Semantic proximity Read ↗

Molecular mechanisms of IL-33–mediated stromal interactions in cancer metastasisSemantic proximity Read ↗

Obesity-mediated upregulation of the YAP/IL33 signaling axis promotes an immunosuppressive tumor microenvironment in breast cancerSemantic proximity Read ↗

Exploring the role of interleukin 11 in cancer progression, patient survival, and therapeutic insightsSemantic proximity Read ↗

IL-33 signaling contributes to the pathogenesis of myeloproliferative neoplasmsSemantic proximity Read ↗

Langerhans islets induce anti-tumor immunity at the expense of glycemic control and predict chemotherapy response in pancreatic cancerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.